Shares Held by Insiders

Fully Diluted Shares Held by Insiders

Date

Name

Buy/Sell

$ Value

# Shares

Avg. Price

Title

Chief Financial Officer

Chief Business Officer

See Remarks

ATAI Life Sciences N.V., a clinical-stage biopharmaceutical company, engages in acquiring, incubating, and developing various therapeutics to treat depression, anxiety, addiction, and other mental health disorders. Its principal clinical programs include RL-007, a pro-cognitive neuromodulator for cognitive impairment associated with schizophrenia; GRX-917, a deuterated etifoxine for anxiety disorders; VLS-01 a N,N-Dimethyltryptamine for treatment resistant depression (TRD); DMX-1002, an oral formulation of ibogaine, a cholinergic, glutamatergic and monoaminergic receptor modulator that is a naturally occurring psychedelic product isolated from a West African shrub for the treatment of opioid use disorders (OUD); and EMP-01, an oral formulation of an MDMA derivative being developed for the treatment of post-traumatic stress disorder. The company's other clinical programs comprise PCN-101, a subcutaneous formulation of R-ketamine, as a therapy for psychiatric indications initially focused on TRD; and KUR-101, a formulation of deuterated mitragynine for the treatment of OUD. ATAI Life Sciences N.V. was founded in 2018 and is headquartered in Berlin, Germany with offices in New York and London.

ATAI Life Sciences N.V., a clinical-stage biopharmaceutical company, engages in acquiring, incubating, and developing various therapeutics...

Datesorted ascending	Name	Buy/Sell	$ Value	# Shares	Avg. Price	Title
2024-04-02	Premium	sold	Premium	Premium	Premium	Chief Financial Officer
2024-04-02	Premium	sold	Premium	Premium	Premium	Chief Business Officer
2024-04-02	Premium	sold	Premium	Premium	Premium	See Remarks
2024-03-14	Premium	acquired	Premium	Premium	Premium	Chief Financial Officer
2024-03-14	Premium	acquired	Premium	Premium	Premium	Chief Business Officer
2024-03-14	Premium	acquired	Premium	Premium	Premium	See Remarks
2024-03-14	Premium	acquired	Premium	Premium	Premium	See Remarks
2023-11-16	Premium	bought	Premium	Premium	Premium	See Remarks
2023-09-13	Premium	bought	Premium	Premium	Premium	See Remarks
2023-03-29	Premium	bought	Premium	Premium	Premium	See Remarks
2023-03-29	Premium	bought	Premium	Premium	Premium	-
2022-04-29	Premium	bought	Premium	Premium	Premium	-
2022-04-28	Premium	bought	Premium	Premium	Premium	-
2022-04-27	Premium	bought	Premium	Premium	Premium	-
2022-04-26	Premium	bought	Premium	Premium	Premium	-
2022-04-25	Premium	bought	Premium	Premium	Premium	-
2022-04-22	Premium	bought	Premium	Premium	Premium	-
2022-04-21	Premium	bought	Premium	Premium	Premium	-
2022-04-20	Premium	bought	Premium	Premium	Premium	-
2022-04-19	Premium	bought	Premium	Premium	Premium	-
2022-04-18	Premium	bought	Premium	Premium	Premium	-
2022-04-14	Premium	bought	Premium	Premium	Premium	-
2022-04-12	Premium	bought	Premium	Premium	Premium	-
2022-04-11	Premium	bought	Premium	Premium	Premium	-
2022-04-08	Premium	bought	Premium	Premium	Premium	-

ATAI - ATA Inc-China Stock Price, Fair Value and News

Latest Insider Trading transactions for ATAI